Procept Biorobotics Corporation · NASDAQ:PRCT

Procept Biorobotics — 46th Annual William Blair Growth Stock Conference

27 slides from Procept Biorobotics's conference presentation

Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation and accompanying oral presentation contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including the expected financial results of PROCEPT BioRobotics Corporation (the “Company”). Words such as “anti
Slide 3: Use of Non-GAAP Financial Information
Use of Non-GAAP Financial Information In addition to financial information presented in accordance with U.S. generally accepted accounting principles ("GAAP"), this presentation and the accompanying oral statements include certain non-GAAP financial measures, which include non-GAAP Adjusted EBITDA.
Slide 4: A Large, Underpenetrated BPH Market with a Disciplined Path to Growth
A Large, Underpenetrated BPH Market with a Disciplined Path to Growth • BPH is significantly undertreated ~40 MILLION U.S. men living with BPH • Many patients fear the procedure more than 8M treated or previously treated with medication their condition actively on discontinued 6.7M medication 1.1M d
Slide 5: PROCEPT Biorobotics Stands on a Strong Foundation
PROCEPT Biorobotics Stands on a Strong Foundation The Next Chapter Accelerate Game-changing Procedure Growth Technology Drive Path to Profitability Deep Clinical Evidence Base Advance Evidence and Innovation We are now moving from establishing Aquablation® as a therapy to leading BPH treatment Data
Slide 6: Growing Procedures and Install Base Paired With Strong Reimbursement
Growing Procedures and Install Base Paired With Strong Reimbursement Worldwide Aquablation Procedures 60000 >125K patients treated worldwide >970 50000 global 40000 install base 30000 20000 10000 Category I Reimbursement 0 as of January 1, 2026 2023 2024 2025 Aquablation is ready to move to the stan
Slide 7: Aquablation is Growing Within the BPH Category
Aquablation is Growing Within the BPH Category All BPH Volume Trends (Excluding TURP) 100,000 Rezum Urolift Aquablation 50,000 Enucleation Greenlight Simple Prostatectomy - 2020 2021 2022 2023 2024 2025 2026 E* Aquablation trending towards becoming the leading modern surgical BPH treatment Data on F
Slide 8: Aquablation is Closing the Gap with TURP
Aquablation is Closing the Gap with TURP Resective BPH Volume Trends 250,000 Aquablation 200,000 Enucleation Greenlight 100,000 Simple Prostatectomy TURP - 2020 2021 2022 2023 2024 2025 2026 E* Aquablation is now the leading resective BPH treatment – second only to TURP Data on File at PROCEPT BioRo
Slide 9: Aquablation Delivers a Complete Solution Across All Prostate Sizes
Aquablation Delivers a Complete Solution Across All Prostate Sizes PRIORITIZE TURP & PVP PRIORITIZE Sexual Function Symptom and Continence Relief Preservation MIST Enucleation & Simple Sexual Function and Continence Symptom Preservation Relief A COMPLETE SOLUTION FOR BPH Resective Non-Resective Comp
Slide 10: Most Important Factors Impacting Which Surgery to Choose
Most Important Factors Impacting Which Surgery to Choose Risk of bladder control issues after surgery 68% Minimizing the likelihood of needing another procedure/surgery 64% Magnitude of symptom relief 58% Recovery time and ease 51% Risk of erectile dysfunction 49% Risk of needing a catheter after su
Slide 11: These procedures involve a 24F catheter in the urethra
These procedures involve a 24F catheter in the urethra – no one wants that more than once Patients deserve to have a procedure that offers a complete solution with the best opportunity to avoid a second intervention 11
Slide 12: Patients Want One Procedure Only
Patients Want One Procedure Only 100% Simple Prostatectomy Aquablation HoLEP Re-operation-free rate (%) 95% REFERENCE TURP STANDARD 90% Rezūm PVP UroLift 85% 80% PAE 75% 0 1 2 3 4 5 6 7 8 9 10 Time after index procedure (years) Rubin B, et al. National review of re-operation rates for modern benign
Slide 14: Realignment of the Commercial Organization
Realignment of the Commercial Organization HISTORICAL MODEL REALIGNMENT Clinical Procedure Procedure Team Support Area Vice Presidents Sales Support Regional Directors Capital Clinical Sales Distinct management structures, Procedure Support Support independent goals and incentives This realignment e
Slide 15: We Have Formed Dedicated Launch Teams
We Have Formed Dedicated Launch Teams NEW LAUNCH TEAM MODEL In pilot accounts in Q42025, we saw a ~50% reduction in Capital Procedure time from PO to first Team Team ten cases Launch New Grow existing Accounts procedures The net result is a dedicated launch team of experts who standardize the pathwa
Slide 16: Greenfield Placements Remain Core to Capital Revenue
Greenfield Placements Remain Core to Capital Revenue Greenfield Placements Targeted Exploring Replacement Remain Primary Driver Strategy Leasing Pilots ~70% of Greenfield unit ASP Alternative capital acquisition strategies enable us to expand access to additional customer groups 16
Slide 18: Prostate Cancer Is A Multifocal Disease Requiring A Whole Gland Treatment
Prostate Cancer Is A Multifocal Disease Requiring A Whole Gland Treatment Prostate cancer is not a focal disease, and focal treatment is limited >40% of patients with GG2 cancer on one side of the prostate had unidentified GG2 cancer on the other side at final pathology1 Visible on MRI Not visible o
Slide 19: WATER IV PCa: Aquablation vs. Prostatectomy RCT
WATER IV PCa: Aquablation vs. Prostatectomy RCT Trial design 6-Month 12-Month Ten Year Follow-up Endpoint Key Secondary with Annual Comparative Analyses FDA Analysis Endpoint Aquablation N = 210 Follow-up continues regardless of additional treatments Year 10 Long term follow-up will capture the Co-P
Slide 20: We Believe Aquablation Will Play an Important Role in Treatment of Prostate Cancer
We Believe Aquablation Will Play an Important Role in Treatment of Prostate Cancer 1 2 3 Prostate Cancer is a multi-focal Aquablation therapy can treat the Growing body of clinical evidence disease that requires a whole whole gland including the supports Aquablation can gland treatment peripheral zo
Slide 21: Recent Milestones Achieved to Advance Prostate Cancer Program
Recent Milestones Achieved to Advance Prostate Cancer Program PIVOTAL WATER IV RP WATER IV AS • Aquablation vs Radical Prostatectomy • Aquablation vs Active Surveillance Both studies will Study Design • • 3:1 Randomization Prospective • • 2:1 Randomization Prospective Randomized assess disease contr
Slide 23: Strong track record of driving growth, expanding margins and scaling efficiently
Strong track record of driving growth, expanding margins and scaling efficiently Total Revenue Gross Margin EBITDA Loss* ($M) (%) ($M) $86.5 $309 61.1% 63.7% 52.2% $68.0 49.4% $60.1 $225 $50.2 $136 $75 2022 2023 2024 2025 2022 2023 2024 2025 2022 2023 2024 2025 Revenue Margin Expansion Improved +60%
Slide 24: Global Revenue Profile and 2027 Revenue Drivers
Global Revenue Profile* Global Revenue ($ mil) +25% to 30% $390 - $410 2027 Revenue Drivers +27% to 33% • Growing U.S. Install Base $308 +37% • Increased Replacement Revenue $224.47 • Stable handpiece & system pricing +65% • Continued penetration of UK + Japan market 2024 2025 2026 2027 *2026 + 2027
Slide 25: How to Achieve 68% to 70% gross margin by 2027
How to Achieve 68% to 70% gross margin by 2027*... • Favorable Unit Margin Annual Gross Margin Targets Handpiece • HP revenue will be tailwind to multi-year gross margin expansion as percent of global revenue increases 68-70% 65% • Declining mix of system revenue will reduce pressure 64% Capital on
Slide 26: Once positive, adjusted EBITDA is expected to achieve sustained positive momentum
Once positive, adjusted EBITDA1,2 is expected to achieve sustained positive momentum Adjusted EBITDA SG&A Leverage Drivers ($-mil) • Improved sales force +$25 to +$30 productivity • Initiate hybrid clinical support model 2023 2024 2025 2026 2027 -$30 to -$17 • SG&A is expected to drive leverage desp
Slide 27: Thank You
THANK YOU 27

PROCEPT BioRobotics — 46th Annual William Blair Growth Stock Conference on 6ix

Procept Biorobotics — 46th Annual William Blair Growth Stock Conference

Slide 1: The Next Chapter for PROCEPT

Slide 2: Safe Harbor Statement

Slide 3: Use of Non-GAAP Financial Information

Slide 4: A Large, Underpenetrated BPH Market with a Disciplined Path to Growth

Slide 5: PROCEPT Biorobotics Stands on a Strong Foundation

Slide 6: Growing Procedures and Install Base Paired With Strong Reimbursement

Slide 7: Aquablation is Growing Within the BPH Category

Slide 8: Aquablation is Closing the Gap with TURP

Slide 9: Aquablation Delivers a Complete Solution Across All Prostate Sizes

Slide 10: Most Important Factors Impacting Which Surgery to Choose

Slide 11: These procedures involve a 24F catheter in the urethra

Slide 12: Patients Want One Procedure Only

Slide 13: Unlocking Growth: A Closer Look

Slide 14: Realignment of the Commercial Organization

Slide 15: We Have Formed Dedicated Launch Teams

Slide 16: Greenfield Placements Remain Core to Capital Revenue

Slide 17: Prostate Cancer: Our Next Frontier

Slide 18: Prostate Cancer Is A Multifocal Disease Requiring A Whole Gland Treatment

Slide 19: WATER IV PCa: Aquablation vs. Prostatectomy RCT

Slide 20: We Believe Aquablation Will Play an Important Role in Treatment of Prostate Cancer

Slide 21: Recent Milestones Achieved to Advance Prostate Cancer Program

Slide 22: Financial Outlook

Slide 23: Strong track record of driving growth, expanding margins and scaling efficiently

Slide 24: Global Revenue Profile and 2027 Revenue Drivers

Slide 25: How to Achieve 68% to 70% gross margin by 2027

Slide 26: Once positive, adjusted EBITDA is expected to achieve sustained positive momentum

Slide 27: Thank You